Table 1.

Clinical characteristics of all 4467 samples and the 2990 ER positive samples from the 40 datasets.

Parameter		Total		OPG low		OPG high		OR	P‐Value
All tumors (n = 4467)
Lymph node status	LNN	2040	62.5%	1142	62.1%	898	63.0%	1.0
	N+	1225	37.5%	697	37.9%	528	37.0%		n.s.
Age	Age >50	1908	61.1%	977	61.8%	931	60.3%	0.9
	Age ≤50	1217	38.9%	604	38.2%	613	39.7%		n.s.
Tumor size	≤2 cm	358	20.3%	197	20.5%	161	20.1%	1.0
	>2 cm	1403	79.7%	763	79.5%	640	79.9%		n.s.
Grade	G3	1524	49.2%	798	49.0%	726	49.4%	1.0
	G1 & G2	1575	50.8%	831	51.0%	744	50.6%		n.s.
ER status	Positive	2990	66.9%	1756	70.4%	1234	62.5%	0.7
	Negative	1477	33.1%	737	29.6%	740	37.5%		<0.001
PgR status	Positive	2466	55.2%	1234	49.5%	1232	62.4%	1.7
	Negative	2001	44.8%	1259	50.5%	742	37.6%		<0.001
HER2 status	Positive	589	13.2%	318	12.8%	271	13.7%	1.1
	Negative	3878	86.8%	2175	87.2%	1703	86.3%		n.s.
Molecular subtype (Hugh et al.)	HER2	381	8.5%	198	7.9%	183	9.3%	1.2
	Luminal A	1442	32.3%	740	29.7%	702	35.6%	1.3
	Luminal B	1548	34.7%	1016	40.8%	532	27.0%	0.5
	Triple negative	1096	24.5%	539	21.6%	557	28.2%	1.4	<0.001
Systemic treatment	Untreated	1108	38.3%	654	36.8%	454	40.6%	1.2
	Endocrine only	1182	40.8%	765	43.1%	417	37.3%
	Chemotherapy	604	20.9%	357	20.1%	247	22.1%		0.008
Outcome variable	RFS	1412	50.9%	740	47.6%	672	55.1%	1.3
	DMFS	1361	49.1%	813	52.4%	548	44.9%		<0.001
ER positive tumors (n = 2990), only parameters significant among all 4467 samples above
PgR status	Positive	2088	69.8%	1080	61.5%	1008	81.7%	2.8
	Negative	902	30.2%	676	38.5%	226	18.3%		<0.001
Molecular subtype (Hugh et al.)	Luminal A	1442	48.2%	740	42.1%	702	59.9%	1.8
	Luminal B	1548	51.8%	1016	57.9%	532	43.1%		<0.001
Systemic treatment	Untreated	750	34.6%	448	32.9%	302	37.4%	1.2
	Endocrine only	1102	50.9%	718	52.8%	384	47.6%
	Chemotherapy	315	14.5%	194	14.3%	121	15.0%		<0.001
Outcome variable	RFS	1011	50.1%	548	47.0%	463	54.5%	1.4
	DMFS	1006	49.9%	619	53.0%	387	45.5%		0.001